Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Linkoeping | OTHER |
| Lund University Hospital | OTHER |
| Sahlgrenska University Hospital | OTHER |
| Karolinska University Hospital |
Not provided
Not provided
Not provided
Not provided
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
This is a multicenter pragmatic prospective observational study including Nordic hospitals treating patients with borderline resectable and locally advanced pancreatic cancer. Eligibility will be assessed at regional multidisciplinary tumor boards. Patients with borderline resectable and locally advanced (non-endocrine) pancreatic cancer according to the National Comprehensive Cancer Network (NCCN) and the International Study Group of Pancreatic Surgery (ISGPS) are eligible for inclusion. The study is observational. Quality of life will be assessed in all study participants. The primary outcomes are exploration rates, resection rates and overall survival.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Median Overall Survival | Median overall survival for patients with locally advanced pancreatic cancer stratified for treatment allocation | From date of inclusion until the date of death from any cause, assessed up to 72 months |
| Resection | Rates of resection among patients with locally advanced pancreatic cancer stratified for treatment allocation | From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months |
| Measure | Description | Time Frame |
|---|---|---|
| Oncological treatment compliance | Number of patients that complete a started oncological treatment and are able to complete regimen | From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months |
| Chemotherapy response |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with a confirmed or suspected non-endocrine invasive pancreatic primary tumor that is classified as borderline resectable or locally advanced disease
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Oskar Franklin, MD/PhD | Contact | +46730458558 | oskar.franklin@umu.se | |
| Agneta Karhu | Contact | agneta.karhu@umu.se |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Surgical Clinic at Umeå University Hospital | Recruiting | Umeå | 90185 | Sweden |
Not provided
| OTHER |
| University Hospital, Umeå | OTHER |
Not provided
Not provided
Not provided
Plasma biobanking. Tissue Microarray Construction from formalin fixed paraffin embedded tissue
Percentage within each RECIST strata |
| From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months |
| Predictors of resectability | Logistic regression models assessing predictors of resectability | From the time of inclusion to end of study follow up or date of death from any cause, whichever came first, up to 72 months |
| Quality of Life at baseline | Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health | At first visit/inclusion |
| Quality of Life at 3 months after inclusion | Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health | Quality of Life at 3 months after inclusion |
| Quality of Life at 6 months after inclusion | Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health | Quality of Life at 6 months after inclusion |
| Quality of Life at 9 months after inclusion | Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health | Quality of Life at 9 months after inclusion |
| Quality of Life at 12 months after inclusion | Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health | Quality of Life at 12 months after inclusion |
| Quality of Life at 24 months after inclusion | Quality of life assessed with EORTC QLQ C30 focused on self-reported Global Health Score ranging from 1 to 7 where a higher number indicates better self-experienced health | Quality of Life at 24 months after inclusion |
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| D010182 | Pancreatic Diseases |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D004066 | Digestive System Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided